ArticlePloS one2018
Inhibition of EV71 by curcumin in intestinal epithelial cells.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Mucosal Immunity: The Key to Combating Enteroviruses and Beyond.Journal of immunology research · 2026Review
- A skin organoid-based infection platform identifies an inhibitor specific for HFMD.Nature communications · 2025Article
- Curcumin, an active component of turmeric: biological activities, nutritional aspects, immunological, bioavailability, and human health benefits - a comprehensive review.Frontiers in immunology · 2025Review
- Clinical Trial Findings and Drug Development Challenges for Curcumin in Infectious Disease Prevention and Treatment.Life (Basel, Switzerland) · 2024Review
- Assessment of Antimicrobial and Cytotoxic Activities of Liposomes Loaded with Curcumin andBiomolecules · 2024Article
- Advances in anti-EV-A71 drug development research.Journal of advanced research · 2024Review
- Role of protein Post-translational modifications in enterovirus infection.Frontiers in microbiology · 2024Review
- Antiviral plant-derived natural products to combat RNA viruses: Targets throughout the viral life cycle.Letters in applied microbiology · 2022Review
- Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions.Metabolites · 2022Review
- Design and various in silico studies of the novel curcumin derivatives as potential candidates against COVID-19 -associated main enzymes.Computational biology and chemistry · 2022Article
- Curcumin and Its Analogs as a Therapeutic Strategy in Infections Caused by RNA Genome Viruses.Food and environmental virology · 2022Review
- Antimicrobial Potential of Curcumin: Therapeutic Potential and Challenges to Clinical Applications.Antibiotics (Basel, Switzerland) · 2022Review
- Curcumin assists anti-EV71 activity of IFN-α by inhibiting IFNAR1 reduction in SH-SY5Y cells.Gut pathogens · 2022Article
- Curcumin: Biological Activities and Modern Pharmaceutical Forms.Antibiotics (Basel, Switzerland) · 2022Review
- Antiviral Therapeutic Potential of Curcumin: An Update.Molecules (Basel, Switzerland) · 2021Review
- Isolation and Identification ofFrontiers in pharmacology · 2021Article
- Curcumin as an Antiviral Agent.Viruses · 2020Review
- Host-Directed Antiviral Therapy.Clinical microbiology reviews · 2020Review
- Cell-Type Specific Metabolic Response of Cancer Cells to Curcumin.International journal of molecular sciences · 2020Article
- Immunocompetent and Immunodeficient Mouse Models for Enterovirus 71 Pathogenesis and Therapy.Viruses · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EV71 is a positive-sense single-stranded RNA virus that belongs to the Picornaviridae family. EV71 infection may cause various symptoms ranging from hand-foot-and-mouth disease to neurological pathological conditions such as aseptic meningitis, ataxia, and acute transverse myelitis. There is currently no effective treatment or vaccine available. Various compounds have been examined for their ability to restrict EV71 replication. However, most experiments have been performed in rhabdomyosarcoma or Vero cells. Since the gastrointestinal tract is the entry site for this pathogen, we anticipated that orally ingested agents may exert beneficial effects by decreasing virus replication in intestinal epithelial cells. In this study, curcumin (diferuloylmethane, C21H20O6), an active ingredient of turmeric (Curcuma longa Linn) with anti-cancer properties, was investigated for its anti-enterovirus activity. We demonstrate that curcumin treatment inhibits viral translation and increases host cell viability. Curcumin does not exert its anti-EV71 effects by modulating virus attachment or virus internal ribosome entry site (IRES) activity. Furthermore, curcumin-mediated regulation of mitogen-activated protein kinase (MAPK) signaling pathways is not involved. We found that protein kinase C delta (PKCδ) plays a role in virus translation in EV71-infected intestinal epithelial cells and that curcumin treatment decreases the phosphorylation of this enzyme. In addition, we show evidence that curcumin also limits viral translation in differentiated human intestinal epithelial cells. In summary, our data demonstrate the anti-EV71 properties of curcumin, suggesting that ingestion of this phytochemical may protect against enteroviral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.